Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
September 21, 2024 04:15 ET
|
Teva Pharmaceutical Industries Ltd
As a leader in neuroscience, Teva is committed to researching new treatment innovations that may help address unmet needs in treating schizophrenia, including TEV-‘749Currently, there is no...
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
September 21, 2024 04:10 ET
|
Teva Pharmaceutical Industries Ltd
As a leader in neuroscience, Teva remains committed to helping address unmet needs in the treatment of schizophrenia through scientific and clinical advances that support optimal treatment options and...
Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
September 20, 2024 18:36 ET
|
Sanofi - Aventis Groupe
Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant ...
SAGE INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Case
September 20, 2024 16:18 ET
|
Robbins Geller Rudman & Dowd LLP
SAN DIEGO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sage Therapeutics, Inc. (NASDAQ: SAGE) securities between April 12, 2021...
Squamous Cell Carcinoma Clinical Trial Pipeline Insights: 75+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space | DelveInsight
September 20, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Squamous Cell Carcinoma Clinical Trial Pipeline Insights: 75+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space |...
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Sage Therapeutics, Inc. (SAGE)
September 20, 2024 12:49 ET
|
Glancy Prongay & Murray LLP
LOS ANGELES, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming October 28, 2024 deadline to file a lead plaintiff motion in the class...
NEOLIFE annonce son résultat semestriel 2024
September 20, 2024 12:00 ET
|
NEOLIFE
Un EBITDA de 419 k€ en forte progression et un résultat positif de 2 k€ NEOLIFE® (Euronext Growth : FR0011636083 – ALNLF), (la...
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
September 20, 2024 09:00 ET
|
FN Media Group LLC
PALM BEACH, Fla., Sept. 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer...
Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade
September 20, 2024 08:57 ET
|
Ipsen Pharma
European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary cholangitis (PBC), a rare liver diseaseApproval follows...
Corporate and Municipal CUSIP Request Volumes Surge in August
September 20, 2024 08:30 ET
|
CUSIP Global Services
NORWALK, Conn., Sept. 20, 2024 (GLOBE NEWSWIRE) -- CUSIP Global Services (CGS) today announced the release of its CUSIP Issuance Trends Report for August 2024. The report, which tracks the issuance...